KRAS and neoplasm: For example, the consistent enrichment of p-Erk in high-grade regions, even within tumors with a lower overall tumor grade, supports our hypothesis that the localized loss of Mek/Erk regulation beyond the activation of the Ras-Raf-Mek-Erk pathway by oncogenic Kras mutation may drive tumor overall progression.